Literature DB >> 28950293

Corrigendum: mdw197, mdw434 and mdw695.

.   

Abstract

Year:  2018        PMID： 28950293      PMCID： PMC6887690          DOI： 10.1093/annonc/mdx336

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors:  S Loibl; I Majewski; V Guarneri; V Nekljudova; E Holmes; E Bria; C Denkert; C Schem; C Sotiriou; S Loi; M Untch; P Conte; R Bernards; M Piccart; G von Minckwitz; J Baselga
Journal:  Ann Oncol       Date:  2016-05-13       Impact factor: 32.976

2.  Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Authors:  S M Swain; A Schneeweiss; L Gianni; J J Gao; A Stein; M Waldron-Lynch; S Heeson; M S Beattie; B Yoo; J Cortes; J Baselga
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

3.  Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Authors:  W Shi; T Jiang; P Nuciforo; C Hatzis; E Holmes; N Harbeck; C Sotiriou; L Peña; S Loi; D D Rosa; S Chia; A Wardley; T Ueno; J Rossari; H Eidtmann; A Armour; M Piccart-Gebhart; D L Rimm; J Baselga; L Pusztai
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.